Indeed, combined ICI and anti-IL-6 or anti-IL-6R Abs have been reported to potentially enhance anti-tumor immunity or reduce immune-related toxicity in preclinical (Mace et al., 2018; Hailemichael et al., 2022) and clinical studies (Fa’ak et al., 2023). Here, IL6R is linked to neoplasm.